IP Library › Granted Patent US 10,342,782
Granted Patent B2
US 10,342,782 · App. 15/661,786 · Granted Jul 9, 2019

Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Inventors: Craig W. Lindsley (Brentwood, TN); P. Jeffrey Conn (Nashville, TN); Darren W. Engers (Brentwood, TN); Carrie K. Jones (Nashville, TN); Thomas M. Bridges (Nashville, TN); Changho Han (Nashville, TN); Andrew S. Felts (Brentwood, TN)
Assignee: Vanderbilt University
A61K31/4196A61K31/166A61K31/381A61K31/4162A61K31/437C07D495/14Y02A50/401
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,342,782
App. No.
15/661,786
Granted
Jul 9, 2019
Kind
B2
Abstract

Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Claims (51)

1. A compound of formula (Ia),

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 4 -C 6 heterocyclyl, halo, and —OR;

R 2 is hydrogen or C 1 -C 6 alkyl;

R 3a and R 3b are each independently selected from hydrogen and C 1 -C 6 alkyl, or R 3a and R 3b are taken together with the nitrogen atom to which they are attached to form an optionally substituted ring;

R 4 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heteroalkyl, heterocyclyl, and —(CR a R b ) n —Z, any of which may be optionally substituted;

R a and R b are each hydrogen;

each R 5 is independently selected from hydrogen and C 1 -C 6 alkyl;

Z is selected from halo, —OR, —SR, —C(O)R, —C(O)OR, —S(O)R, —SO 2 R, —NR 2 , —C(O)NR 2 , —S(O) 2 NR 2 , aryl, heteroaryl, cycloalkyl, and heterocyclyl, any of which may be optionally substituted;

n is 1, 2, 3, 4, 5, 6, 7, or 8; and

each R is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, heteroaryl, heteroarylalkyl, and heteroalkyl, any of which may be optionally substituted.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from hydrogen and chloro.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl.

4. The compound claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3b are each hydrogen.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 4 is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, and —(CR a R b ) n —Z, any of which may be optionally substituted.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 4 is selected from 2,3-dihydro-1H-indenyl and 6,7-dihydro-5H-cyclopenta[b]pyridinyl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 4 is —(CR a R b ) n —Z;

n is 1;

R a and R b are each hydrogen; and

Z is phenyl substituted with 1 or 2 substituents selected from halo, heterocyclyl, alkoxy, and —SO 2 R.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 4 is heterocyclyl selected from azetidinyl and pyrrolidinyl;

the heterocyclyl is substituted with one substituent selected from phenyl, pyridinyl, pyrimidinyl, pyrazinyl, and 1,3,4-oxadiazolyl; and

the phenyl, pyridinyl, pyrimidinyl and pyrazinyl groups are substituted with 0, 1 or 2 substituents selected from halo, alkyl, haloalkyl and cycloalkyl; and

the 1,3,4-oxadiazolyl group is substituted with 0 or 1 substituent selected from alkyl and cycloalkyl.

9. The compound of claim 1 , selected from the group consisting of:

6-amino-N-(6,7-dihydro-5H-cyclopenta[b]pyridin-6-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(2,3-dihydro-1H-inden-2-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

(S)-6-amino-N-(2,3-dihydro-1H-inden-1-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(3,4-difluorophenyl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(4-methoxybenzyl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-2,5-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-2,5-dimethyl-N-(4-(4-methylpiperazin-1-yl)benzyl)thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(3-fluoro-4-methoxybenzyl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(5-cyclopropyl-3-methylpyridin-2-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(2,5-dichloropyridin-4-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(6-chloro-2-methylpyrimidin-4-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

(S)-6-amino-N-(1-(5-fluoropyridin-2-yl)pyrrolidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(2-cyclopropylpyrimidin-5-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-2,5-dimethyl-N-(1-(5-(trifluoromethyl)pyrimidin-2-yl)azetidin-3-yl)thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

(R)-6-amino-N-(1-(5-fluoropyridin-2-yl) pyrrolidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(5-chloro-2-(trifluoromethyl)pyridin-4-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(5-chloropyrazin-2-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

6-amino-N-(1-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide; and

6-amino-N-(1-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)azetidin-3-yl)-2,5-dimethylthieno[3,2-e][1,2,4]triazolo[1,5-a]pyridine-7-carboxamide;

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is isotopically labeled.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2017
From: LINDSLEY, CRAIG W.; CONN, P. JEFFREY; ENGERS, DARREN W.; JONES, CARRIE K.; BRIDGES, THOMAS M.; HAN, CHANGHO; FELTS, ANDREW S.
To: VANDERBILT UNIVERSITY
Reel/Frame 043151/0587 →
Continuity (2)
Provisional Application 62367342 · Jul 27, 2016
Related Publication 20180028501A1 · Feb 1, 2018